Prasterone 6.5 mg (0.50%) Vaginal Insert

DRUG2 trials

Sponsors

EndoCeutics Inc.

Conditions

Hypoactive Sexual Desire DisorderHypoactive Sexual Desire Disorder (HSDD)

Phase 3

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

CompletedNCT03287232

EndoCeutics Inc.Hypoactive Sexual Desire Disorder

Start: 2017-10-16End: 2019-07-22Updated: 2021-04-09

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

WithdrawnNCT03619005

EndoCeutics Inc.Hypoactive Sexual Desire Disorder (HSDD)

Start: 2018-11-13End: 2019-12-06Updated: 2020-07-31